A Case of Polyneuropathy Following a Single Dose of Diethylcarbamazine and Albendazole During Mass Administration of Drug - A Case Report
Keywords:Albendazole, DEC, Polyneuropathy
The global program to eliminate Lymphatic Filariasis created by The World Health organization in 1997 is based on mass administration of single annual doses of diethylcarbamazine ( DEC) plus albendazole in non African regions and of albendazole plus ivermectin in Africa. The usual side effects of DEC treatment include fever, chills, arthralgia, headaches, nausea, and vomiting. Albendazole is associated with relatively few side effects consisting of occasional nausea, vomiting, abdominal pain, headache, reversible alopecia, elevated aminotransferases and rarely leucopenia and rash. We report a case of polyneuropathy in a young individual following DEC and albendazole during mass drug administration.
Keywords: Albendazole; DEC; Polyneuropathy.
Nepal Journal of Medical Sciences. 2012; 1(1): 56-58
How to Cite
Copyright © by Nepal Journal of Medical Sciences. The ideas and opinions expressed by authors of articles summarized, quoted, or published in full text in this Journal represents only opinions of authors and do not necessarily reflect the official policy of Nepal Journal of Medical Sciences or the institute with which the author(s) is (are) affiliated, unless so specified.